Why Cytokinetics, Incorporated (CYTK) stock moved
Cytokinetics, Incorporated (CYTK) shares tumbled 7.5% to $72.09 as of August 29, 2026, a significant decline from the prior close of $77.90. BestStocks flagged the session as a major change for CYTK. Below, we break down what changed for CYTK, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
CYTK fell 7.5% to $72.09
CYTK tumbled 7.5% in its latest session, moving from $77.90 to $72.09.
What it means for Cytokinetics, Incorporated investors
For Cytokinetics, Incorporated investors, the recent signals add up to a strong bearish shift. On the constructive side: CYTK moved +3.08% from its $78.94 open to a $81.37 close on 2026-08-06; Cytokinetics, Incorporated (CYTK) moved +2.53% from $79.11 to $81.11 on 2026-07-21. Weighing against that: Material negative event; Sharp 7.5% decline — elevated risk. Wall Street's consensus price target sits at $109.91, implying +52.5% upside from $72.09. Over the past 90 days analysts logged 1 upgrade and 0 downgrades. BestStocks rates the overall signal quality medium (65/100). With earnings roughly 67 days out, the next report is the most likely near-term test of the move.
CYTK price reaction
CYTK last traded at $72.09, down $5.81 (-7.46%) from the previous close of $77.90. The session traded on 1.9× average volume (above avg), so the move carried above-average conviction. Over the past month the stock has ranged between $72.09 and $81.37, and it currently sits about 0% of the way up that band.
Bullish and bearish analyst opinions on Cytokinetics, Incorporated (CYTK)
The consensus analyst price target on Cytokinetics, Incorporated (CYTK) is $109.91, 52.5% above the recent $72.09. Over the past 90 days analysts logged 1 upgrade, 9 maintains, and 0 downgrades. Here is how the bullish and bearish cases on CYTK line up.
The bullish case
- Wall Street's consensus price target of $109.91 implies +52.5% upside from $72.09.
- The Street's most bullish target is $140.00 (+94.2%).
- 1 analyst upgrade in the past 90 days, most recently UBS to Buy (2026-06-29).
- CYTK moved +3.08% from its $78.94 open to a $81.37 close on 2026-08-06.
- Cytokinetics, Incorporated (CYTK) moved +2.53% from $79.11 to $81.11 on 2026-07-21.
The bearish case
- Material negative event.
- Sharp 7.5% decline — elevated risk.
- Cytokinetics, Incorporated (CYTK) moved -5.50% from $81.23 to $76.76 on 2026-08-07.
Weighing both sides, BestStocks' composite read of recent signals is strongly bearish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Aug 29, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for CYTK
In-depth CYTK event analyses
Frequently asked questions about CYTK
Why did Cytokinetics, Incorporated (CYTK) stock move?
CYTK tumbled 7.5% to $72.09. No single company-specific catalyst was confirmed during the move window, and it looks technical.
How much did CYTK stock fall?
CYTK lost 7.46% ($5.81) versus the prior close of $77.90, last trading at $72.09 on 1.9× average volume.
When is Cytokinetics, Incorporated's next earnings date?
CYTK's next earnings report is estimated for 2026-11-04 — about 67 days away.
What is the analyst price target for CYTK?
The consensus analyst price target for CYTK is $109.91, about 52.5% above the current $72.09. Over the past 90 days, analysts recorded 1 upgrade, 9 maintains, and 0 downgrades.
How BestStocks tracks CYTK
This page is generated automatically by BestStocks' change-detection system after its price and volume cleared CYTK-specific materiality thresholds, triggering an evidence check. It draws on 18 tracked change events for CYTK, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of August 29, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.